The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
Antigen-specific regulatory T cells (Tregs) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis (LN), a severe manifestation of SLE, is strongly associated with autoreactivity to the Smith (Sm) autoantigen and the human leucocyte antigen (HLA)-DR15 haplotype.
To explore the therapeutic opportunity of these associations, Eggenhuizen et al. published an article in Nature Communications, investigating the potential of Sm-specific Tregs (Sm-Tregs) to suppress LN.1 Here, we summarize the key insights.
Figure 1. Sm-Tregs suppress autoimmunity in samples from patients with SLE in vitro*
IFN, interferon; IL, interleukin; SLE, systemic lupus erythematosus; Sm, Smith; TCR, T cell receptor; Treg, regulatory T cells.
Data are presented as mean.
*Adapted from Eggenhuizen, et al.1
†p < 0.0332.
‡p < 0.0021.
Figure 2. Sm-Tregs suppress disease in humanized mouse models of LN*
LN, lupus nephritis; NS, non-significant; Sm, Smith; TCR, T-cell receptor; Treg, regulatory T cells.
*Adapted from Eggenhuizen, et al.1
†p < 0.0332.
‡p < 0.0021.
§p < 0.0002.
‖p < 0.0001.
Data are presented as mean.
Key learnings |
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content